Big Red Alphas gave out ice cream and information on Saturday in an attempt to raise funds and awareness about a genetic condition. Alpha-1 antitrypsin deficiency is a condition that affects the lungs ...

A gene-editing delivery system developed by UT Southwestern Medical Center researchers simultaneously targeted the liver and ...

The global alpha-1 antitrypsin deficiency (AATD) market is expanding, driven by advances in diagnosis, treatment, and growing awareness. Key players like Grifols, CSL Behring, and Pfizer lead ...

AIRNA’s lead program has the potential to be a best-in-class therapeutic for alpha-1 antitrypsin deficiency (AATD). AIRNA has headquarters in Cambridge, MA, with research operations in Tübingen ...

According to recent projections by Future Market Insights (FMI), the global alpha-1 antitrypsin deficiency market is poised for significant growth, reaching an estimated USD 10 Billion by 2033, up ...

Alpha-1-antitrypsin is a so-called protease inhibitor, a type of enzyme inhibitor. It is produced in the liver but exerts its effects in the lungs, where it regulates immune cell activity.

Alpha-1-antitrypsin is a so-called protease inhibitor, a type of enzyme inhibitor. It is produced in the liver but exerts its effects in the lungs, where it regulates immune cell activity. This ...

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...

Quiver AI Summary Korro Bio, Inc. announced that its investigational drug KRRO-110 has received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin Deficiency (AATD).

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency Provided by GlobeNewswire Mar 14, 2025 12:00pm ...